Asheville, NC, Feb. 18, 2021 – GenesisCare — one of the leading oncology providers in
the United States, Australia, Spain, and the United Kingdom — today announced the
addition of the new Elekta Versa HD™ at its Asheville location. This innovative
technology is available to oncology patients with brain, lung, and metastases cancer
throughout Western North Carolina and nearby areas. With shorter treatment times, this
hypofractionated radiation therapy provides the highest level of dose delivery accuracy
while pushing the boundaries of stereotactic capabilities that can be delivered in a
standard therapy slot of 15 minutes or less, which was not previously possible.
“Our new Elekta linear accelerator greatly enhances our ability to offer our patients
cutting-edge radiotherapy by allowing precise shaping of the radiation beam to the
target by minimizing dose to adjacent normal tissue,” said Dr. Daniel G. Baseman, MD,
Radiation Oncology Specialist for GenesisCare. “The treatments are administered with
great speed, which reduces therapy times substantially. In turn, our patients’ direct
experience is enhanced along with improved accuracy and quality of delivery.”
This advanced technology therapy is just in time to raise the bar and awareness for
cancer treatment during (and beyond) Cancer Awareness Month (February). Data
trends show an increased risk of mortality for breast, lung, and pancreatic cancer up to
3.2% , with a decreased survival every day that treatment is delayed beyond nine
weeks. Coupled with today’s unprecedented rise in increased mortality for late-stage
cancer patients due to delayed testing and treatment during COVID, the need for
dynamic cancer therapy like Elekta Vera HD is crucial.
With advanced radiation therapy capabilities like no other technology in the region, this
hypofractionated therapy provides state-of-the-art treatment options for the most
challenging cases. As a 2020 recipient of the Best in KLAS award , the Elekta Versa HD
was ranked highest in the Radiation Therapy equipment category with accurate,
stereotactic treatments that offer timely, adaptable service solutions for patients
operating during COVID-19.
“ When used with appropriate patients, this technology allows for high rates of tumor
control and low toxicity,” continued Dr. Baseman. “The ability to deliver high doses of
radiotherapy administered during shorter overall treatment courses expands our
practice capabilities while having the greatest impact on both the patient experience and
outcomes of people with cancer.”
As a leading provider of oncology services globally, GenesisCare strives to ensure its
patients’ best possible life outcomes by bridging the gap between integrated cancer
care, research and development, and medical technology. With its origins in radiation
oncology, GenesisCare has, in recent years, expanded its services to include medical
oncology, urology, and a cutting-edge form of nuclear medicine.
For more information on GenesisCare, visit genesiscare.com (formally 21 st Century
Oncology). To view the full list of precautions GenesisCare US centers are taking to
ensure patient and staff safety, visit https://www.genesiscare.com/us/covid-19/ .